ResearcherJohns Hopkins UniversityActive in the last 2 years

Keyu Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4547-4918; OpenAlex author ID A5062972206. Sources: OpenAlex.

Their work

Papers: 14 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 62

Papers, trials and grants by year

2020: 2 papers · 2021: 1 paper · 2022: 4 papers · 2023: 1 paper · 2024: 5 papers · 2025: 1 paper

Papers 14

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer. First author DOI 10.1186/s40364-024-00721-7 ↗
Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies. Last author DOI 10.1080/1744666x.2024.2348605 ↗
Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827 ↗
Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming. Co-author DOI 10.1126/sciadv.adp0684 ↗
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. Co-author DOI 10.1186/s13045-024-01576-z ↗
Consensus, debate, and prospective on pancreatic cancer treatments. Co-author DOI 10.1186/s13045-024-01613-x ↗
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Co-author DOI 10.1038/s41467-023-39196-9 ↗
Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Co-author DOI 10.1016/j.canlet.2022.215722 ↗
Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001 ↗
Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Co-author DOI 10.1053/j.gastro.2022.06.027 ↗
CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. Co-author DOI 10.1084/jem.20211631 ↗
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. Co-author DOI 10.20892/j.issn.2095-3941.2020.0273 ↗
Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Co-author DOI 10.1016/j.cdtm.2020.01.002 ↗
Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. Co-author DOI 10.1136/jitc-2019-000351 ↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.